Prolactinomas account for approximately 50% of all pituitary adenomas coming to medical
attention and are an important cause of hypogonadism and infertility. The ultimate goal of …

Prolactinomas account for approximately 40% of all pituitary adenomas and are an
important cause of hypogonadism and infertility. The ultimate goal of therapy for …

Simple Summary This review updates recent advances in the pathogenesis, diagnosis, and
therapy of prolactinoma. Prolactinomas, comprising 30–50% of all pituitary neuroendocrine …

Prolactinomas, the most prevalent type of neuroendocrine disease, account for
approximately 40% of all pituitary adenomas. The most important clinical problems …

Dopamine agonists such as bromocriptine and cabergoline are the predominant treatment
drugs for prolactinoma by inhibiting prolactin secretion and shrinking tumor size. However …

Clinically relevant pituitary adenomas are present in about 1 per 1,000 of the general
population and prolactinomas are by far the most common clinical subtype of pituitary …

The discovery of dopamine inhibitory effects on prolactin secretion has led to an era of
successful dopaminergic therapy for prolactinomas. Herein we provide an overview of the …

The authors present an update on the various treatment modalities and discuss
management strategies for prolactinomas. Prolactinomas are the most common type of …

Prolactinomas are the most common hormone-secreting pituitary tumors. Treatment with
dopamine agonists can stabilize disease and recent evidence suggests that in many cases …

Prolactinomas are the most common functional pituitary tumors, accounting for 40% of all
pituitary adenomas. Medical treatment with dopamine agonists (DA), mainly cabergoline, is …